

# Contents

---

<b>Foreword</b>	<b>xv</b>
<b>1. Drug discovery and development: An overview of modern methods and principles</b>	<b>1</b>
Drug discovery and development from 20,000 Feet	11
Target selection: the first step forward	15
Hit identification: finding a starting point	19
Identify a clinical candidate: juggling the properties	25
Questions	31
References	31
<b>2. The drug discovery process: From ancient times to the present day</b>	<b>43</b>
The age of botanicals: pre-industrial drug discovery	44
Early biotherapeutics: before the biotechnology revolution	48
Paul Ehrlich: the father of modern drug discovery	51
Milestones in drug discovery	53
Milestones in animal models: breeding a better model	54
The Wistar rat	54
Immunocompromised mice	55
Transgenic animal models	56
Knockout animal models	58
Milestones in molecular science	60
X-ray crystallography	60
Molecular modeling and computational chemistry	63
High-throughput technology: chemical synthesis and screening science	64
Milestones in biotechnology	70
Recombinant DNA and transfection technology	72
Polymerase chain reaction technology	75
DNA Sequencing and genomics	76
Proteomics	80
Monoclonal antibody and hybridoma technology	83
The rise of biologics and macromolecular therapeutics	86
Societal and governmental impacts	87
The Pure Food and Drug Act of 1906	88
The Elixir of Sulfanilamide Disaster of 1937	89
The Thalidomide story	91
Regulatory milestones	93



Durham-Humphrey Amendment of 1951	94
Kefauver-Harris Amendment of 1962	95
Hatch-Waxman Act of 1984	96
Biologics Price Competition and Innovation Act of 2009	97
Future developments in drug discovery	99
Questions	99
References	100
 3. Classical targets in drug discovery	 111
Protein structure	113
Enzymes	119
Inhibition of enzymes	125
G-protein-coupled receptors	130
G-protein-dependent signaling pathways	133
Cyclic adenosine monophosphate signaling	134
IP <sub>3</sub> signaling	136
$\beta$ -Arrestin pathways	138
G-protein-coupled receptor signaling pathways	140
Modulating G-protein-coupled receptor signaling	141
Ion channels	143
Gating mechanisms	149
Ligand-gated channels	149
Voltage-gated channels	152
Other gating mechanisms	155
Membrane transport proteins (transporters)	156
Nuclear receptors	164
Nuclear receptor signaling pathways	167
Modulating nuclear receptor activity	169
Biomolecular interactions: protein/protein, protein/DNA, and protein/RNA	
interfaces	170
Types of "hot spots" in biomolecular interactions	172
Stabilizing biomolecular interactions	174
Questions	176
References	176
 4. <i>In vitro</i> screening systems	 185
The language of screening: basic terms	186
Concentration—response curves and IC <sub>50</sub> s	187
Dissociation constants ( $K_d$ ) and inhibition constants ( $K_i$ )	188
Efficacy versus binding: EC <sub>50</sub> s	190
Agonist, partial agonist, antagonist, allosteric modulators, and inverse agonists	191
Agonists and partial agonists	192
Antagonists	193
Basal activity and inverse agonist	193
Receptor reserve	193
Allosteric modulation	194



Streptavidin and biotin	195
Biochemical versus cellular assays	196
Assay systems and methods of detection	198
Radioligand systems	199
Scintillation proximity assay	201
Enzyme-linked immunosorbent assay	204
Fluorescence-based assay systems	206
Fluorescence polarization	207
Fluorescence resonance energy transfer	210
Time-resolved fluorescence resonance energy transfer	214
Amplified luminescent proximity homogeneous assay (AlphaScreen™)	217
Fluorescent detection of calcium flux	220
Reporter gene assays	223
Chloramphenicol acetyltransferase	224
$\beta$ -Lactamase reporter assays	224
Luciferase reporter assays	226
Bioluminescence resonance energy transfer assays	228
Kinetic fluorescent measurement systems	230
Label-free assay systems	231
Cellular dielectric spectroscopy	232
Optical biosensors	233
Surface plasmon resonance technology	236
Electrophysiological patch clamp	237
Thermal shift assay	240
High content screening	243
General consideration for all screening methods	245
Questions	248
References	248
<b>5. Medicinal chemistry</b>	<b>257</b>
Structure–activity relationships and structure–property relationships	258
The role of chirality	263
Push and pull in structure–activity relationships	266
Quantitative structure–activity relationships	267
The pharmacophore	272
Developing an structure–activity relationship data set	276
The structure–activity relationship cycle	287
Bioisosterism	288
Structure–activity relationship, selectivity, and physicochemical properties	294
“Drug-like” guidelines	295
Questions	297
References	298
<b>6. <i>In vitro</i> ADME and <i>in vivo</i> pharmacokinetics</b>	<b>305</b>
Absorption	309
Solubility	310
Permeability	315



Distribution	324
Permeability	326
Transporters	328
Plasma protein binding	330
Elimination pathways	332
Metabolism	333
Excretion	345
<i>In vitro</i> ADME model systems	348
<i>In Vivo</i> pharmacokinetics	351
Volume of distribution	353
Clearance	355
Half-life	356
Bioavailability	359
Species selection	362
Questions	362
References	364
 7. Animal models of disease states	 371
Sources of animal models	373
Validity of animal models	376
Species selection	377
Number of animals	378
Exemplary animal models by disease category	378
Animal models in neuroscience	379
The forced swimming test: A model of depression	379
The elevated plus maze: A measure of anxiety	380
The novel object recognition test: A model of memory and cognition	381
Contextual fear conditioning model: A model of contextual learning	382
The Morris water maze: A model of spatial learning and memory	383
Animal models of neurodegeneration	384
The SOD <sup>1G93A</sup> mouse of amyotrophic lateral sclerosis (ALS)	384
The MPTP model of Parkinson's disease	386
Animal models of cardiovascular disease	387
Models of hypertension	387
Models of hyperlipidemia and high cholesterol	389
Models of atrial fibrillation	391
Models of heart failure	393
Animal models of infectious disease	396
Murine thigh infection model	397
Murine model of systemic infection	397
Mouse model of influenza virus infection	398
Limitations of animal models of infection	399
Animal models of oncology	400
Mouse xenograft tumor model	400
Mouse allograft tumor model	401
Genetically engineered mouse models of cancer	402



Animal models of pain	403
The Von Frey test	404
The Ramdall-Selitto test	405
Heat based models	406
Inflammation based models	408
Surgical models	409
General consideration for pain models	409
Animal models of diabetes	409
Animal models of drug addiction	411
Conclusion	413
Questions	414
References	414
 8. Safety and toxicology	 421
Sources of toxicity	423
Acute versus chronic toxicity	430
Cytotoxicity	430
Carcinogenicity, genotoxicity, and mutagenicity	432
Drug-drug interactions	436
Cardiovascular safety and toxicology studies	438
Central nervous system safety and toxicology studies	445
Immune system-mediated safety issues	447
Teratogenicity	450
<i>In vivo</i> toxicity and safety studies	451
Questions	453
References	453
 9. Antibody-drug discovery	 459
IgG structure and function	461
Antibody therapy drug discovery	463
Hybridoma technology	463
Antibody phage display	469
Modified monoclonal antibodies	473
General considerations	476
Conclusion	478
Questions	478
References	478
 10. Basics of clinical trials	 483
Before the clinic	486
Drug supply	486
Delivery methods	489
Formulation	491
Investigational new drug application	502
Phase 1 clinical trials	504



Phase 2 clinical trials	506
Phase 3 clinical trials	510
Phase 4 clinical trials	515
Adaptive clinical trial design	516
Meta-analysis of clinical trial data	517
Questions	519
References	519
<b>11. Translational medicine and biomarkers</b>	<b>523</b>
Definition of a biomarker and their classification	526
Characteristics and impact of biomarkers	529
Biomarkers versus surrogate endpoints	531
Imaging technologies	533
The practical application of biomarkers	540
Dipeptidyl peptidase IV inhibitors (Januvia)	541
Physiological measurements as biomarkers: Orexin antagonists	543
FDG PET imaging agent	545
The neurokinin 1 receptor, depression, and PET imaging:	
The Aprepitant story	546
Cancer biomarkers	548
Conclusion	553
Questions	553
References	554
<b>12. Organizational consideration and trends in the pharmaceutical industry</b>	<b>561</b>
Organizational structures of pharmaceutical companies	562
Business divisions interactions	562
The discovery project team evolutionary cycle	563
The business climate	567
Mergers and acquisitions	567
Contract research organizations	573
Academic drug discovery	575
Funding issues	581
Conclusion	584
Questions	584
Appendix 1	585
References	591
<b>13. Intellectual property and patents in drug discovery</b>	<b>595</b>
Patentable subject matter	597
Inherent properties and patentability	601
Novelty and the prior art	603
Obviousness and the prior art	604
Inventorship	607



Assignment and ownership	609
Classification of patents and patent applications	611
Impact of overlapping patents	612
Patent applications and their contents	612
Contents of a patent application	617
Conclusion	621
Questions	622
References	622
<b>14. Case studies in drug discovery</b>	<b>625</b>
Tamiflu: From mechanism of action to marketed drug	625
Histone deacetylase inhibitors: Physicochemical optimization via structural change	630
HIV protease inhibitors: Chemically complex miracle drugs	632
Nitrofurantoin: A surprisingly successful drug	637
Seldane® (Terfenadine) vs Allegra® (Fexofenadine): Metabolism matters: Safety	639
Claritin® (Loratadine) versus Clarinex® (Desloratadine): Metabolism matters: Pharmacokinetics	642
MPTP: Parkinson's disease in a bottle	644
Bupropion and Methylphenidate: Improving performance via formulation changes	647
Selective inhibition of COX-2: The impact of an inadequate written description	651
Antibiotic resistant bacteria and the development of $\beta$ -lactamase inhibitors	652
Association for Molecular Pathology vs Myriad Genetics: The validity of gene patents	655
Conclusion	658
Questions	659
References	659
Answers to questions in textbook by chapter	665
<b>Subject Index</b>	<b>693</b>
<b>Drug Index</b>	<b>713</b>